Home › Macular Degeneration

Macular Degeneration clinical trials recruiting in the U.S.

55 studies for Macular Degeneration are recruiting participants at sites across the United States.

Macular degeneration, or age-related macular degeneration (AMD), causes vision loss in older adults. Learn about the types and what can help.

Cities with the most studies

• Dallas, TX13 studies
• Erie, PA10 studies
• The Woodlands, TX9 studies
• Hagerstown, MD8 studies
• Sacramento, CA8 studies
• Reno, NV8 studies
• Austin, TX7 studies
• Carmel, IN7 studies
• Houston, TX7 studies
• Fort Worth, TX7 studies
• Salt Lake City, UT7 studies
• Santa Monica, CA7 studies
• Boston, MA7 studies
• Phoenix, AZ7 studies
• Cleveland, OH7 studies
• Washington, DC6 studies
• Cincinnati, OH6 studies
• Portland, OR6 studies
• Nashville, TN6 studies
• Naperville, IL6 studies
• Raleigh, NC6 studies
• Mountain View, CA6 studies
• Columbia, SC6 studies
• Philadelphia, PA6 studies
• McAllen, TX6 studies
• Fort Lauderdale, FL5 studies
• Lynchburg, VA5 studies
• Orlando, FL5 studies
• Syracuse, NY5 studies
• Spokane, WA5 studies
• Tampa, FL5 studies
• San Antonio, TX5 studies
• Eugene, OR5 studies
• San Francisco, CA5 studies
• Pensacola, FL5 studies
• Durham, NC5 studies
• Jacksonville, FL4 studies
• St. Petersburg, FL4 studies
• Memphis, TN4 studies
• Cicero, IL4 studies

By state

• Arizona11 studies
• California20 studies
• Colorado7 studies
• Connecticut6 studies
• Florida14 studies
• Georgia6 studies
• Illinois13 studies
• Indiana7 studies
• Maryland11 studies
• Massachusetts14 studies
• Michigan9 studies
• Minnesota5 studies
• Mississippi5 studies
• Missouri5 studies
• Nevada8 studies
• New Jersey7 studies
• New York10 studies
• North Carolina11 studies
• Ohio11 studies
• Oklahoma3 studies
• Oregon9 studies
• Pennsylvania17 studies
• South Carolina8 studies
• Tennessee7 studies
• Texas24 studies
• Utah9 studies
• Virginia7 studies
• Washington8 studies
• Wisconsin6 studies

Recently updated studies

From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.